The only clinically validated genome-wide NIPS (NIPT), screens all 23 chromosome pairs, reporting aneuploidies, large deletions and duplications greater than 7 Mb in addition to select microdeletions.
Like most NIPSs (NIPTs), MaterniT® GENOME screens for common trisomies (such as 21, 18, and 13) and fetal sex. Like some more comprehensive NIPSs (NIPTs), it also screens for sex chromosome aneuploidies, and analyzes seven clinically significant microdeletion regions.
Unlike any other NIPS (NIPT) to date, MaterniT GENOME also analyzes every chromosome and can provide information about clinically relevant microdeletions and gains or losses of chromosome material ≥ 7 Mb across the genome.
By combining increased sequencing depth with industry-leading expertise, the MaterniT GENOME test offers a breadth of coverage unlike any other noninvasive prenatal screening available to date.
MaterniT GENOME is an ideal fit for high-risk pregnancies where a patient may wish to avoid a diagnostic procedure, or where screening for common aneuploidies may not be enough.
This chart shows a summary of the 453 positive results seen by your peers. To view turnaround times, specimen requirements and other clinical details, view MaterniT GENOME in the test menu.
MaterniT 21 PLUS: the pioneering NIPS (NIPT) with more than 1 million tests run1; screens the more well-known trisomies 21, 18, and 13, fetal sex, and (optionally) clinically relevant microdeletions, sex chromosome aneuploidies, and trisomies 16 and 22.
Introducing the upgraded MaterniT specimen collection kit, featuring new branding for better kit identification and fewer components—including one 10 mL Streck tube instead of two— for improved ease-of-use.
In addition to NIPS (NIPT), we also offer: serum screening; carrier screening, from comprehensive to single-gene; diagnostic testing that can be used on prenatal and products of conception (POC) samples, as well as pediatric, cord blood or adult samples; and hereditary cancer screening.